{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:04:23Z","timestamp":1791234263024,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health","award":["R01 HL-70227"],"award-info":[{"award-number":["R01 HL-70227"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeutic proteins prior to their initial use is critical as it is often difficult to reverse an established immune response. Here, we discuss a rational design and testing of a phosphatidylserine-containing nanoparticle platform for novel oral prophylactic reverse vaccination approach, i.e., pre-treatment of a therapeutic protein in the presence of nanoparticles to prevent immunogenicity of protein therapies.<\/jats:p>","DOI":"10.1038\/s41598-021-97333-0","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T10:02:24Z","timestamp":1631095344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins"],"prefix":"10.1038","volume":"11","author":[{"given":"Nhan H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona Y.","family":"Glassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Dingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam N.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Wohlfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Bankert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathy V.","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"97333_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","volume":"7","author":"M Krishna","year":"2016","unstructured":"Krishna, M. & Nadler, S. G. Immunogenicity to biotherapeutics\u2014the role of anti-drug immune complexes. Front. Immunol. 7, 21. https:\/\/doi.org\/10.3389\/fimmu.2016.00021 (2016).","journal-title":"Front. Immunol."},{"key":"97333_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","volume":"108","author":"R Dingman","year":"2019","unstructured":"Dingman, R. & Balu-Iyer, S. V. Immunogenicity of protein pharmaceuticals. J. Pharm. Sci. 108, 1637\u20131654. https:\/\/doi.org\/10.1016\/j.xphs.2018.12.014 (2019).","journal-title":"J. Pharm. Sci."},{"key":"97333_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1023\/b:pham.0000029275.41323.a6","volume":"21","author":"S Hermeling","year":"2004","unstructured":"Hermeling, S., Crommelin, D. J., Schellekens, H. & Jiskoot, W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21, 897\u2013903. https:\/\/doi.org\/10.1023\/b:pham.0000029275.41323.a6 (2004).","journal-title":"Pharm. Res."},{"key":"97333_CR4","unstructured":"Lumizyme [Package Insert]. (Genzyme Corporation CM, 2011)."},{"key":"97333_CR5","unstructured":"Myozyme [Package Insert]. (Genzyme Corporation CM, 2017)."},{"key":"97333_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria, S. G. et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: Lessons learned from Pompe disease. Genet. Med. 15, 123\u2013131. https:\/\/doi.org\/10.1038\/gim.2012.110 (2013).","journal-title":"Genet. Med."},{"key":"97333_CR7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1055\/s-0037-1615061","volume":"79","author":"CR Hay","year":"1998","unstructured":"Hay, C. R. et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK haemophilia centre directors organisation. Thromb. Haemost. 79, 762\u2013766 (1998).","journal-title":"Thromb. Haemost."},{"key":"97333_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199302183280701","volume":"328","author":"JM Lusher","year":"1993","unstructured":"Lusher, J. M., Arkin, S., Abildgaard, C. F. & Schwartz, R. S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N. Engl. J. Med. 328, 453\u2013459. https:\/\/doi.org\/10.1056\/NEJM199302183280701 (1993).","journal-title":"N. Engl. J. Med."},{"key":"97333_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-4615-1277-6_6","volume":"489","author":"P Lollar","year":"2001","unstructured":"Lollar, P., Healey, J. F., Barrow, R. T. & Parker, E. T. Factor VIII inhibitors. Adv. Exp. Med. Biol. 489, 65\u201373. https:\/\/doi.org\/10.1007\/978-1-4615-1277-6_6 (2001).","journal-title":"Adv. Exp. Med. Biol."},{"key":"97333_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","volume":"18","author":"ZY Zhou","year":"2015","unstructured":"Zhou, Z. Y. et al. Burden of illness: Direct and indirect costs among persons with hemophilia A in the United States. J. Med. Econ. 18, 457\u2013465. https:\/\/doi.org\/10.3111\/13696998.2015.1016228 (2015).","journal-title":"J. Med. Econ."},{"key":"97333_CR11","doi-asserted-by":"publisher","first-page":"17051","DOI":"10.1074\/jbc.C112.396325","volume":"288","author":"P Gaitonde","year":"2013","unstructured":"Gaitonde, P. et al. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. J. Biol. Chem. 288, 17051\u201317056. https:\/\/doi.org\/10.1074\/jbc.C112.396325 (2013).","journal-title":"J. Biol. Chem."},{"key":"97333_CR12","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/jps.24513","volume":"104","author":"R Ramakrishnan","year":"2015","unstructured":"Ramakrishnan, R., Davidowitz, A. & Balu-Iyer, S. V. Exposure of FVIII in the presence of phosphatidyl serine reduces generation of memory B-cells and induces regulatory T-cell-mediated hyporesponsiveness in hemophilia A mice. J. Pharm. Sci. 104, 2451\u20132456. https:\/\/doi.org\/10.1002\/jps.24513 (2015).","journal-title":"J. Pharm. Sci."},{"key":"97333_CR13","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1016\/j.xphs.2016.06.018","volume":"105","author":"JL Schneider","year":"2016","unstructured":"Schneider, J. L. & Balu-Iyer, S. V. Phosphatidylserine converts immunogenic recombinant human acid alpha-glucosidase to a tolerogenic form in a mouse model of pompe disease. J. Pharm. Sci. 105, 3097\u20133104. https:\/\/doi.org\/10.1016\/j.xphs.2016.06.018 (2016).","journal-title":"J. Pharm. Sci."},{"key":"97333_CR14","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.xphs.2018.03.027","volume":"107","author":"FY Glassman","year":"2018","unstructured":"Glassman, F. Y. et al. Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher. J. Pharm. Sci. 107, 2048\u20132054. https:\/\/doi.org\/10.1016\/j.xphs.2018.03.027 (2018).","journal-title":"J. Pharm. Sci."},{"key":"97333_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.clim.2010.10.006","volume":"138","author":"P Gaitonde","year":"2011","unstructured":"Gaitonde, P., Peng, A., Straubinger, R. M., Bankert, R. B. & Balu-Iyer, S. V. Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clin. Immunol. 138, 135\u2013145. https:\/\/doi.org\/10.1016\/j.clim.2010.10.006 (2011).","journal-title":"Clin. Immunol."},{"key":"97333_CR16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.bbamem.2018.06.010","volume":"2126\u20132133","author":"D Kerr","year":"1860","unstructured":"Kerr, D. et al. Sensitivity of peripheral membrane proteins to the membrane context: A case study of phosphatidylserine and the TIM proteins. Biochim. Biophys. Acta Biomembr. 2126\u20132133, 2018. https:\/\/doi.org\/10.1016\/j.bbamem.2018.06.010 (1860).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"97333_CR17","doi-asserted-by":"publisher","first-page":"E1463","DOI":"10.1073\/pnas.1320174111","volume":"111","author":"GT Tietjen","year":"2014","unstructured":"Tietjen, G. T. et al. Molecular mechanism for differential recognition of membrane phosphatidylserine by the immune regulatory receptor Tim4. Proc. Natl. Acad. Sci. USA 111, E1463-1472. https:\/\/doi.org\/10.1073\/pnas.1320174111 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"97333_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/path.1970","volume":"209","author":"P Verbrugghe","year":"2006","unstructured":"Verbrugghe, P. et al. Murine M cells express annexin V specifically. J. Pathol. 209, 240\u2013249. https:\/\/doi.org\/10.1002\/path.1970 (2006).","journal-title":"J. Pathol."},{"key":"97333_CR19","doi-asserted-by":"publisher","first-page":"e2215","DOI":"10.1038\/cddis.2016.113","volume":"7","author":"P Cunin","year":"2016","unstructured":"Cunin, P. et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 7, e2215. https:\/\/doi.org\/10.1038\/cddis.2016.113 (2016).","journal-title":"Cell Death Dis."},{"key":"97333_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1600-0854.2007.00590.x","volume":"8","author":"CE Futter","year":"2007","unstructured":"Futter, C. E. & White, I. J. Annexins and endocytosis. Traffic 8, 951\u2013958. https:\/\/doi.org\/10.1111\/j.1600-0854.2007.00590.x (2007).","journal-title":"Traffic"},{"key":"97333_CR21","doi-asserted-by":"publisher","first-page":"27559","DOI":"10.1074\/jbc.M202879200","volume":"277","author":"Y Kawasaki","year":"2002","unstructured":"Kawasaki, Y., Nakagawa, A., Nagaosa, K., Shiratsuchi, A. & Nakanishi, Y. Phosphatidylserine binding of class B scavenger receptor type I, a phagocytosis receptor of testicular sertoli cells. J. Biol. Chem. 277, 27559\u201327566. https:\/\/doi.org\/10.1074\/jbc.M202879200 (2002).","journal-title":"J. Biol. Chem."},{"key":"97333_CR22","doi-asserted-by":"publisher","first-page":"16221","DOI":"10.1074\/jbc.270.27.16221","volume":"270","author":"A Rigotti","year":"1995","unstructured":"Rigotti, A., Acton, S. L. & Krieger, M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270, 16221\u201316224. https:\/\/doi.org\/10.1074\/jbc.270.27.16221 (1995).","journal-title":"J. Biol. Chem."},{"key":"97333_CR23","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1172\/JCI11348","volume":"106","author":"HL Weiner","year":"2000","unstructured":"Weiner, H. L. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J. Clin. Investig. 106, 935\u2013937. https:\/\/doi.org\/10.1172\/JCI11348 (2000).","journal-title":"J. Clin. Investig."},{"key":"97333_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","volume":"241","author":"HL Weiner","year":"2011","unstructured":"Weiner, H. L., da Cunha, A. P., Quintana, F. & Wu, H. Oral tolerance. Immunol. Rev. 241, 241\u2013259. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01017.x (2011).","journal-title":"Immunol. Rev."},{"key":"97333_CR25","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","volume":"148","author":"VA Fadok","year":"1992","unstructured":"Fadok, V. A. et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207\u20132216 (1992).","journal-title":"J. Immunol."},{"key":"97333_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0024-3205(96)00315-3","volume":"59","author":"PR Bar","year":"1996","unstructured":"Bar, P. R. Apoptosis\u2013the cell\u2019s silent exit. Life Sci. 59, 369\u2013378. https:\/\/doi.org\/10.1016\/0024-3205(96)00315-3 (1996).","journal-title":"Life Sci."},{"key":"97333_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrrheum.2010.46","volume":"6","author":"LE Munoz","year":"2010","unstructured":"Munoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280\u2013289. https:\/\/doi.org\/10.1038\/nrrheum.2010.46 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"97333_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature06307","volume":"450","author":"M Miyanishi","year":"2007","unstructured":"Miyanishi, M. et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 450, 435\u2013439. https:\/\/doi.org\/10.1038\/nature06307 (2007).","journal-title":"Nature"},{"key":"97333_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2007.11.008","volume":"27","author":"C Santiago","year":"2007","unstructured":"Santiago, C. et al. Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity 27, 941\u2013951. https:\/\/doi.org\/10.1016\/j.immuni.2007.11.008 (2007).","journal-title":"Immunity"},{"key":"97333_CR30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.immuni.2007.11.011","volume":"27","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi, N. et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27, 927\u2013940. https:\/\/doi.org\/10.1016\/j.immuni.2007.11.011 (2007).","journal-title":"Immunity"},{"key":"97333_CR31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1053\/j.gastro.2007.08.006","volume":"133","author":"PC Yang","year":"2007","unstructured":"Yang, P. C. et al. TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigen-specific Th2 differentiation and intestinal allergy. Gastroenterology 133, 1522\u20131533. https:\/\/doi.org\/10.1053\/j.gastro.2007.08.006 (2007).","journal-title":"Gastroenterology"},{"key":"97333_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0006-291x(75)80433-5","volume":"63","author":"RL Juliano","year":"1975","unstructured":"Juliano, R. L. & Stamp, D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 63, 651\u2013658. https:\/\/doi.org\/10.1016\/s0006-291x(75)80433-5 (1975).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"97333_CR33","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1074\/jbc.M112.438507","volume":"288","author":"SC Frasch","year":"2013","unstructured":"Frasch, S. C. et al. Neutrophils regulate tissue Neutrophilia in inflammation via the oxidant-modified lipid lysophosphatidylserine. J. Biol. Chem. 288, 4583\u20134593. https:\/\/doi.org\/10.1074\/jbc.M112.438507 (2013).","journal-title":"J. Biol. Chem."},{"key":"97333_CR34","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.1039\/c6cc03669d","volume":"52","author":"DR Rice","year":"2016","unstructured":"Rice, D. R., Clear, K. J. & Smith, B. D. Imaging and therapeutic applications of zinc(II)-dipicolylamine molecular probes for anionic biomembranes. Chem. Commun. 52, 8787\u20138801. https:\/\/doi.org\/10.1039\/c6cc03669d (2016).","journal-title":"Chem. Commun."},{"key":"97333_CR35","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1016\/S0021-9258(19)34062-1","volume":"265","author":"HA Andree","year":"1990","unstructured":"Andree, H. A. et al. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J. Biol. Chem. 265, 4923\u20134928 (1990).","journal-title":"J. Biol. Chem."},{"key":"97333_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0167-5699(97)01053-0","volume":"18","author":"HL Weiner","year":"1997","unstructured":"Weiner, H. L. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18, 335\u2013343 (1997).","journal-title":"Immunol. Today"},{"key":"97333_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1146\/annurev.iy.12.040194.004113","volume":"12","author":"HL Weiner","year":"1994","unstructured":"Weiner, H. L. et al. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12, 809\u2013837. https:\/\/doi.org\/10.1146\/annurev.iy.12.040194.004113 (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"97333_CR38","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/BF01955757","volume":"38","author":"OG Bjornsson","year":"1982","unstructured":"Bjornsson, O. G., Murphy, R. & Chadwick, V. S. Physiochemical studies of indocyanine green (ICG): Absorbance\/concentration relationship, pH tolerance and assay precision in various solvents. Experientia 38, 1441\u20131442. https:\/\/doi.org\/10.1007\/BF01955757 (1982).","journal-title":"Experientia"},{"key":"97333_CR39","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1021\/bi500021j","volume":"53","author":"JC Kraft","year":"2014","unstructured":"Kraft, J. C. & Ho, R. J. Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: The basis for near-infrared imaging in vivo. Biochemistry 53, 1275\u20131283. https:\/\/doi.org\/10.1021\/bi500021j (2014).","journal-title":"Biochemistry"},{"key":"97333_CR40","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1021\/acsami.6b16801","volume":"9","author":"HJ Yoon","year":"2017","unstructured":"Yoon, H. J., Lee, H. S., Lim, J. Y. & Park, J. H. Liposomal indocyanine green for enhanced photothermal therapy. ACS Appl. Mater Interfaces 9, 5683\u20135691. https:\/\/doi.org\/10.1021\/acsami.6b16801 (2017).","journal-title":"ACS Appl. Mater Interfaces"},{"key":"97333_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","volume":"301","author":"X Wang","year":"2016","unstructured":"Wang, X., Terhorst, C. & Herzog, R. W. In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol. 301, 18\u201329. https:\/\/doi.org\/10.1016\/j.cellimm.2015.10.001 (2016).","journal-title":"Cell Immunol."},{"key":"97333_CR42","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.4049\/jimmunol.170.5.2516","volume":"170","author":"T Oida","year":"2003","unstructured":"Oida, T. et al. CD4+CD25\u2212 T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J. Immunol. 170, 2516\u20132522. https:\/\/doi.org\/10.4049\/jimmunol.170.5.2516 (2003).","journal-title":"J. Immunol."},{"key":"97333_CR43","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3389\/fimmu.2018.02625","volume":"9","author":"W Huang","year":"2018","unstructured":"Huang, W., Solouki, S., Carter, C., Zheng, S. G. & August, A. Beyond type 1 regulatory T cells: Co-expression of LAG3 and CD49b in IL-10-producing T cell lineages. Front. Immunol. 9, 2625. https:\/\/doi.org\/10.3389\/fimmu.2018.02625 (2018).","journal-title":"Front. Immunol."},{"key":"97333_CR44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nm.3179","volume":"19","author":"N Gagliani","year":"2013","unstructured":"Gagliani, N. et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 19, 739\u2013746. https:\/\/doi.org\/10.1038\/nm.3179 (2013).","journal-title":"Nat. Med."},{"key":"97333_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","volume":"3","author":"A Schmidt","year":"2012","unstructured":"Schmidt, A., Oberle, N. & Krammer, P. H. Molecular mechanisms of treg-mediated T cell suppression. Front. Immunol. 3, 51. https:\/\/doi.org\/10.3389\/fimmu.2012.00051 (2012).","journal-title":"Front. Immunol."},{"key":"97333_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fimmu.2019.00043","volume":"10","author":"M Romano","year":"2019","unstructured":"Romano, M., Fanelli, G., Albany, C. J., Giganti, G. & Lombardi, G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front. Immunol. 10, 43. https:\/\/doi.org\/10.3389\/fimmu.2019.00043 (2019).","journal-title":"Front. Immunol."},{"key":"97333_CR47","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T cells: How do they suppress immune responses?. Int. Immunol. 21, 1105\u20131111. https:\/\/doi.org\/10.1093\/intimm\/dxp095 (2009).","journal-title":"Int. Immunol."},{"key":"97333_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009 (2008).","journal-title":"Cell"},{"key":"97333_CR49","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.4049\/jimmunol.175.7.4180","volume":"175","author":"HW Lim","year":"2005","unstructured":"Lim, H. W., Hillsamer, P., Banham, A. H. & Kim, C. H. Cutting edge: Direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. 175, 4180\u20134183. https:\/\/doi.org\/10.4049\/jimmunol.175.7.4180 (2005).","journal-title":"J. Immunol."},{"key":"97333_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev.immunol.14.1.275","volume":"14","author":"MR Neutra","year":"1996","unstructured":"Neutra, M. R., Pringault, E. & Kraehenbuhl, J. P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 14, 275\u2013300. https:\/\/doi.org\/10.1146\/annurev.immunol.14.1.275 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"97333_CR51","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mi.2013.30","volume":"6","author":"NA Mabbott","year":"2013","unstructured":"Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R. & Mahajan, A. Microfold (M) cells: Important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 6, 666\u2013677. https:\/\/doi.org\/10.1038\/mi.2013.30 (2013).","journal-title":"Mucosal Immunol."},{"key":"97333_CR52","doi-asserted-by":"publisher","first-page":"e0158775","DOI":"10.1371\/journal.pone.0158775","volume":"11","author":"KL Hilligan","year":"2016","unstructured":"Hilligan, K. L., Connor, L. M., Schmidt, A. J. & Ronchese, F. Activation-induced TIM-4 expression identifies differential responsiveness of intestinal CD103+ CD11b+ dendritic cells to a mucosal adjuvant. PLoS ONE 11, e0158775. https:\/\/doi.org\/10.1371\/journal.pone.0158775 (2016).","journal-title":"PLoS ONE"},{"key":"97333_CR53","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1084\/jem.20180019","volume":"215","author":"TN Shaw","year":"2018","unstructured":"Shaw, T. N. et al. Tissue-resident macrophages in the intestine are long lived and defined by Tim-4 and CD4 expression. J. Exp. Med. 215, 1507\u20131518. https:\/\/doi.org\/10.1084\/jem.20180019 (2018).","journal-title":"J. Exp. Med."},{"key":"97333_CR54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.immuni.2013.12.012","volume":"40","author":"E Mazzini","year":"2014","unstructured":"Mazzini, E., Massimiliano, L., Penna, G. & Rescigno, M. Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1(+) macrophages to CD103(+) dendritic cells. Immunity 40, 248\u2013261. https:\/\/doi.org\/10.1016\/j.immuni.2013.12.012 (2014).","journal-title":"Immunity"},{"key":"97333_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood.2019000658","volume":"134","author":"HM van den Berg","year":"2019","unstructured":"van den Berg, H. M. et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood 134, 317\u2013320. https:\/\/doi.org\/10.1182\/blood.2019000658 (2019).","journal-title":"Blood"},{"key":"97333_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00560","author":"L Graca","year":"2018","unstructured":"Graca, L. & Waldmann, H. Inducing immune tolearnce to therapeutic protein, cells and tissues. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.00560 (2018).","journal-title":"Front. Immunol."},{"key":"97333_CR57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","volume":"80","author":"N Raben","year":"2003","unstructured":"Raben, N. et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 80, 159\u2013169. https:\/\/doi.org\/10.1016\/j.ymgme.2003.08.022 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"97333_CR58","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jps.21102","volume":"97","author":"K Ramani","year":"2008","unstructured":"Ramani, K. et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J. Pharm. Sci. 97, 1386\u20131398. https:\/\/doi.org\/10.1002\/jps.21102 (2008).","journal-title":"J. Pharm. Sci."},{"key":"97333_CR59","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","volume":"234","author":"GR Bartlett","year":"1959","unstructured":"Bartlett, G. R. Phosphorus assay in column chromatography. J. Biol. Chem. 234, 466\u2013468 (1959).","journal-title":"J. Biol. Chem."},{"key":"97333_CR60","unstructured":"Balu-Iyer, S. V., Ramani, K. & Straubinger, R. M. Method of complexing a protein by the use of a dispersed system and proteins thereof. U.S Patent No. 7625584 (U.S. Patent and Trademark Office, 2009)."},{"key":"97333_CR61","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/jps.20340","volume":"94","author":"K Ramani","year":"2005","unstructured":"Ramani, K., Purohit, V. S., Miclea, R. D., Middaugh, C. R. & Balasubramanian, S. V. Lipid binding region (2303\u20132332) is involved in aggregation of recombinant human FVIII (rFVIII). J. Pharm. Sci. 94, 1288\u20131299 (2005).","journal-title":"J. Pharm. Sci."},{"key":"97333_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0038-1653759","volume":"73","author":"B Verbruggen","year":"1995","unstructured":"Verbruggen, B. et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: Improved specificity and reliability. Thromb. Haemost. 73, 247\u2013251 (1995).","journal-title":"Thromb. Haemost."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97333-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T20:47:21Z","timestamp":1673210841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97333-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97333"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97333-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17853"}}